Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04022616 · ClinicalTrials.gov registry record
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
A clinical trial of Breast Cancer, sponsored by Ohio State University Comprehensive Cancer Center.
- Recruiting
- Registry status
- 99
- Enrollment target
- 1
- Study location
NCT04022616: Recruiting study of Breast Cancer, sponsored by Ohio State University Comprehensive Cancer Center.
NCT04022616 is a study of Breast Cancer that is actively recruiting participants, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 99 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04022616, a study of Breast Cancer, is actively recruiting participants, sponsored by Ohio State University Comprehensive Cancer Center.
- RECRUITING
- Registry status
- 99 participants
- Enrollment target
- 1
- Study location
Study Summary
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
Primary Outcome
Function of Natural Killer Cells will be studied by measuring their ability to kill target cancer cells coated with monoclonal antibodies. isolate unfavorable immune cells called Myeloid Derived Suppressor Cells (MDSC) from the peripheral blood or the tumors of study subjects and test how strongly they inhibit function of favorable immune cells called Natural Killer Cells. Function of Natural Killer Cells will be studied by measuring their ability to kill target cancer cells coated with monoclo
Conditions Studied
Interventions
- OTHER Specimen collection
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2010-06-04 |
| Est. Completion | 2025-12-31 |
What NCT04022616 shows while recruiting
NCT04022616 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Specimen collection is the first listed.
NCT04022616 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04022616 about?
NCT04022616 is a clinical study titled "Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients". Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
What is the current status of trial NCT04022616?
This trial is currently recruiting. The enrollment target is 99 participants. The study started on 2010-06-04. Estimated completion is 2025-12-31.
What conditions does trial NCT04022616 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT04022616?
The interventions under investigation include: Specimen collection (OTHER).
Who is sponsoring clinical trial NCT04022616?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04022616 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04022616's enrollment target sits among peer trials
99 596th of 1224 higher than 628 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
- NCT04302025 · 99 participants · Phase 2
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI